Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Santhera Pharmaceuticals

- PMLiVE

Santhera Secures Agreement with Uniphar for the Distribution of AGAMREE® (Vamorolone) in five GCC (Gulf Cooperation Council) Countries

Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Uniphar to manage the distribution of AGAMREE® (vamorolone) in the United Arab Emirates, the Kingdom of Saudi Arabia,...

Uniphar

- PMLiVE

Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC

Almost 1,700 people are diagnosed with bladder cancer in Scotland annually

- PMLiVE

Santhera’s Duchenne muscular dystrophy drug Agamree accepted by SMC

The rare muscle-wasting disorder affects approximately 2,500 males in the UK at any one time

- PMLiVE

NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree

Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision

- PMLiVE

Chiesi’s rare disorder therapies approved by SMC for Fabry disease and epidermolysis bullosa

Rare diseases currently affect around 436,000 people living in Scotland

- PMLiVE

Bristol Myers Squibb’s Opdualag approved by SMC for advanced melanoma

The fifth-most common cancer in the UK affects more than 1,200 people in Scotland every year

- PMLiVE

Santhera’s Duchenne muscular dystrophy drug shows promise as long-term treatment

The muscle-wasting disorder is estimated to affect one in every 3,500 male births worldwide

- PMLiVE

Novartis’ Consentyx granted approval by SMC to treat hidradenitis suppurativa

The drug is available in Scotland on the NHS to treat the chronic inflammatory condition

- PMLiVE

MHRA approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

EU flag

EC approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

- PMLiVE

Bristol Myers Squibb’s Sotyktu accepted by SMC for plaque psoriasis

More than 133,520 people in Scotland are affected by the inflammatory condition

- PMLiVE

FDA approves Santhera’s Duchenne muscular dystrophy drug Agamree

The rare muscle-wasting disorder is estimated to affect one in 3,500 male births worldwide

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links